A 12-month role-over study to evaluate the efficacy of sustain release formulation of human recombinant growth hormone (Eutropin Plus) as compared to standard daily rhGH (Eutropin) in prepubertal children with growth hormone deficiency.

Trial Profile

A 12-month role-over study to evaluate the efficacy of sustain release formulation of human recombinant growth hormone (Eutropin Plus) as compared to standard daily rhGH (Eutropin) in prepubertal children with growth hormone deficiency.

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Nov 2015

At a glance

  • Drugs Somatropin (Primary) ; Somatropin
  • Indications Somatotropin deficiency
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Nov 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top